<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18133" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Barbiturates</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Skibiski</surname>
            <given-names>Jeanie</given-names>
          </name>
          <aff>Missouri State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeanie Skibiski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18133.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Barbiturates are a category of sedative-hypnotic medications used for treating seizure disorders, neonatal withdrawal, insomnia, preoperative anxiety, and the induction of coma to address increased intracranial pressure (ICP). In addition, these medications are also helpful for inducing anesthesia.&#x000a0;Thiopental, introduced in 1934 for general anesthesia induction, served as the primary intravenous anesthetic induction agent until propofol replaced it.&#x000a0;Barbiturates approved by the US Food and Drug Administration (FDA) for clinical use&#x000a0;include&#x000a0;phenobarbital, methohexital, butalbital, pentobarbital, primidone, and amobarbital.</p>
        <p>Various barbiturates have been either discontinued or substituted with benzodiazepines. Given the prevalence of drug-drug interactions in specific populations, the collaborative efforts of the interprofessional team, including primary care, emergency medicine, and/or specialists, are essential for devising the most effective management plan based on best practices. This activity outlines the indications, mechanism of action, pharmacokinetics, administration, adverse effects, contraindications, and toxicology of certain barbiturates. Clinicians involved will examine the monitoring parameters encompassing a wide range of physiological considerations when employing barbiturates in the clinical setting, along with crucial aspects in the care management of patients using these substances.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for barbiturate use in various clinical scenarios, such as seizure disorders, neonatal withdrawal, insomnia, and induction of anesthesia.</p></list-item><list-item><p>Implement safe and evidence-based practices when administering barbiturates, including proper dosing, monitoring, and adjusting for individual patient needs.</p></list-item><list-item><p>Assess patients regularly for signs of adverse effects and monitor therapeutic efficacy, adapting treatment plans as necessary.</p></list-item><list-item><p>Collaborate with the interprofessional healthcare team, including primary care, emergency medicine, and specialists, to develop comprehensive management plans for patients using barbiturates.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18133&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18133">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18133.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Barbiturates are a category of sedative-hypnotic medications used for treating seizure disorders, neonatal withdrawal, insomnia, preoperative anxiety, and the induction of coma to address increased intracranial pressure (ICP). In addition, these medications are also helpful for inducing anesthesia.&#x000a0;Thiopental was introduced in 1934 for general anesthesia induction.<xref ref-type="bibr" rid="article-18133.r1">[1]</xref>&#x000a0;This drug was the predominant intravenous (IV) anesthetic induction agent until propofol replaced it.<xref ref-type="bibr" rid="article-18133.r2">[2]</xref>&#x000a0;In refractory status epilepticus, a Cochrane Review found that thiopental was equally effective as propofol for controlling seizure activity.<xref ref-type="bibr" rid="article-18133.r3">[3]</xref> In 2011, the primary supplier of thiopental chose to cease its production due to its involvement in lethal injection procedures, resulting in its unavailability in the United States.<xref ref-type="bibr" rid="article-18133.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Barbiturates approved by the US Food and Drug Administration (FDA) for clinical use are provided below.&#x000a0;</p>
        <p><bold>Phenobarbital:&#x000a0;</bold>Phenobarbitone has extensive use as an antiepileptic drug in the neonatal and pediatric population. It is the most cost-effective drug treatment for epilepsy in adults in low-resource countries.<xref ref-type="bibr" rid="article-18133.r5">[5]</xref>&#x000a0;IV barbiturates have been used for neurosurgery due to reduced cerebral metabolic rate of oxygen consumption.<xref ref-type="bibr" rid="article-18133.r6">[6]</xref> For individuals with severe traumatic brain injury (TBI), high-dose barbiturates may be a consideration but are not indicated for prophylactic administration.<xref ref-type="bibr" rid="article-18133.r7">[7]</xref>&#x000a0;In a review of practice in&#x000a0;5 European countries, about 20% of patients received barbiturates.<xref ref-type="bibr" rid="article-18133.r8">[8]</xref></p>
        <p>In refractory status epilepticus, a Cochrane Review found that thiopental was equally effective as propofol for controlling seizure activity.<xref ref-type="bibr" rid="article-18133.r3">[3]</xref><bold>&#x000a0;</bold>A systematic review and meta-analysis evaluated interventions for benzodiazepine-resistant status epilepticus in both children and adults. Among the studied interventions, phenobarbital and high-dose levetiracetam were superior to phenytoin in achieving seizure cessation within 60 minutes. Phenobarbital is effective, but concerns about its safety profile exist, including&#x000a0;cardiovascular instability.<xref ref-type="bibr" rid="article-18133.r9">[9]</xref></p>
        <p><bold>Methohexital:&#x000a0;</bold>Methohexital has demonstrated safety and&#x000a0;efficacy for procedural sedation of short duration for cardioversion&#x000a0;and&#x000a0;pediatric outpatient surgery.<xref ref-type="bibr" rid="article-18133.r10">[10]</xref><xref ref-type="bibr" rid="article-18133.r11">[11]</xref>&#x000a0;Methohexital can be used for&#x000a0;fracture reduction in the emergency department&#x000a0;and sedation for elective intubation in neonates.<xref ref-type="bibr" rid="article-18133.r12">[12]</xref><xref ref-type="bibr" rid="article-18133.r13">[13]</xref>&#x000a0;Methohexital has preferential use in electroconvulsive therapy due to longer seizure duration.<xref ref-type="bibr" rid="article-18133.r6">[6]</xref></p>
        <p><bold>Butalbital:&#x000a0;</bold>Butalbital is used primarily for the treatment of headache disorders.&#x000a0;The combination of butalbital and acetaminophen is approved for relieving symptoms associated with tension-type headaches.<xref ref-type="bibr" rid="article-18133.r14">[14]</xref>&#x000a0;A combination of acetaminophen-butalbital-caffeine is also available. Severe acetaminophen-butalbital-caffeine&#x000a0;withdrawal&#x000a0;has been described.<xref ref-type="bibr" rid="article-18133.r15">[15]</xref>&#x000a0;The combination of butalbital-aspirin-caffeine is FDA-approved for tension-type headaches.&#x000a0;Medications incorporating butalbital demonstrate a 2-fold increased risk for the development of medication overuse headaches when contrasted with the usage of simple analgesics and triptans.<xref ref-type="bibr" rid="article-18133.r16">[16]</xref><xref ref-type="bibr" rid="article-18133.r17">[17]</xref></p>
        <p><bold>Pentobarbital:&#x000a0;</bold>Pentobarbital is used as a pre-anesthetic medication&#x000a0;for status epilepticus.<xref ref-type="bibr" rid="article-18133.r18">[18]</xref>&#x000a0;Pentobarbital is used off-label for&#x000a0;TBI associated with refractory elevated ICP.<xref ref-type="bibr" rid="article-18133.r19">[19]</xref></p>
        <p><bold>Primidone:&#x000a0;</bold>Primidone is prescribed for the treatment of seizure disorders. According to the American Academy of Neurology (AAN), the choice between primidone (a barbiturate) and propranolol for essential tremors depends on comorbidities and potential adverse drug reactions.<xref ref-type="bibr" rid="article-18133.r20">[20]</xref></p>
        <p><bold>Amobarbital:&#x000a0;</bold>Amobarbital has a labeled indication for&#x000a0;insomnia, but the American Association of Sleep Medicine does not endorse its use.<xref ref-type="bibr" rid="article-18133.r21">[21]</xref></p>
      </sec>
      <sec id="article-18133.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Barbiturates cause postsynaptic enhancement of gamma-aminobutyric acid (GABA), interacting with alpha- and beta subunits of the GABA-A receptor.<xref ref-type="bibr" rid="article-18133.r22">[22]</xref>&#x000a0;Barbiturates increase chloride ion flux, resulting in postsynaptic hyperpolarization and central nervous system (CNS) depression. Phenobarbital and pentobarbital affect the GABA-A receptors with a dose-dependent response. These drugs activate chloride channels at higher micromolar concentrations associated with anesthetic levels.<xref ref-type="bibr" rid="article-18133.r23">[23]</xref>&#x000a0;Although both barbiturates and benzodiazepines interact with GABA-A receptors, they are unique because they potentiate GABA-A receptors while increasing chloride ion influx even with very low concentrations of the GABA neurotransmitter.<xref ref-type="bibr" rid="article-18133.r24">[24]</xref></p>
        <p>
<bold>Structure-Activity Relationship</bold>
</p>
        <p>Barbituric acid was the basis of many formulations patented by the Bayer company. Due to its low lipophilicity, barbituric acid had no innate&#x000a0;CNS activity. A lipophilic derivative of barbituric acid was developed (barbital: 5,5-diethylbarbituric acid) and successfully induced sleep in dogs.<xref ref-type="bibr" rid="article-18133.r23">[23]</xref>&#x000a0;</p>
        <p>Amylobarbitone became the first IV anesthetic used in 1928. The formulation of parenteral dosage forms&#x000a0;occurred due to the addition of sodium at the C2 position.<xref ref-type="bibr" rid="article-18133.r25">[25]</xref>&#x000a0;Lipophilicity was enhanced by Volviler and Tabern with the addition of a sulfur group while replacing an oxygen atom, creating the thiobarbiturates in 1934.<xref ref-type="bibr" rid="article-18133.r25">[25]</xref>&#x000a0;In 1957, methohexital was created by Stoelting by adding an aliphatic side chain at carbon 5, along with methylation of the nitrogen atom.<xref ref-type="bibr" rid="article-18133.r24">[24]</xref>&#x000a0;The<italic toggle="yes"> R</italic>(+) enantiomer of many barbiturates produces excitatory effects, while the <italic toggle="yes">S</italic>(&#x02212;) enantiomers produce more depressant effects.<xref ref-type="bibr" rid="article-18133.r26">[26]</xref>&#x000a0;</p>
        <p>
<bold>Classification of&#x000a0;Barbiturates</bold>
</p>
        <p>Barbiturates are classified according to the duration of their action. The short- and intermediate-acting ones have effects lasting 2 to 6 hours, while long-acting barbiturates exert their effects for longer than 6 hours.<xref ref-type="bibr" rid="article-18133.r27">[27]</xref><xref ref-type="bibr" rid="article-18133.r28">[28]</xref></p>
        <p><bold>Ultra-short-acting:</bold> This category of barbiturates includes methohexital and thiopental.</p>
        <p><bold>Short-acting:</bold>&#x000a0;This category of&#x000a0;barbiturates includes pentobarbital and secobarbital.</p>
        <p><bold>Intermediate-acting:</bold> This category of barbiturates includes&#x000a0;amobarbital and butalbital.</p>
        <p><bold>Long-acting:</bold> This category of barbiturates includes phenobarbital and primidone.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Phenobarbital is rapidly absorbed with a time-to-peak concentration&#x000a0;of 2 to 4 hours. The bioavailability of phenobarbital is approximately 90% in adults and less in neonatal populations.<xref ref-type="bibr" rid="article-18133.r29">[29]</xref>&#x000a0;Sodium salts of barbiturates are absorbed more rapidly, and food delays the onset of action of orally administered barbiturates. The IV&#x000a0;route is usually reserved for managing status epilepticus (phenobarbital sodium) or the induction or maintenance of general anesthesia (eg, methohexital or thiopental). Thiopental observes first-order kinetics in low doses of 5 mg/kg boluses. In high-dose or prolonged infusions, non-linear kinetics will occur due to the progressive saturation of enzyme systems.<xref ref-type="bibr" rid="article-18133.r30">[30]</xref></p>
        <p><bold>Distribution:</bold> Highly lipid-soluble barbiturates cross the blood-brain barrier rapidly, but rapid redistribution from the CNS to peripheral tissues occurs.<xref ref-type="bibr" rid="article-18133.r28">[28]</xref>&#x000a0;Thiopental and methohexital undergo rapid redistribution after IV injections into less-vascular tissues, particularly muscle and fat, decreasing the concentration of barbiturates in the plasma and brain.&#x000a0;Terminating the effect of a single bolus IV injection of thiopental occurs by redistribution from the central compartment to peripheral compartments.<xref ref-type="bibr" rid="article-18133.r31">[31]</xref></p>
        <p><bold>Metabolism:</bold> The oxidation of barbiturates is the most important biotransformation that terminates biological activity. In addition, n-glycosylation is important for the metabolism of phenobarbital. Phenobarbital is metabolized extensively by the cytochrome P450, and the maturation of this enzyme family mainly occurs during the neonatal period.<xref ref-type="bibr" rid="article-18133.r32">[32]</xref><xref ref-type="bibr" rid="article-18133.r33">[33]</xref>&#x000a0;</p>
        <p>Repeated administration of phenobarbital decreases the half-life due to the induction of microsomal enzymes. The self-induced increase in barbiturate metabolism partially accounts for tolerance to barbiturates. In addition, with chronic administration, an increase in aminolevulinic acid (ALA) synthetase enzymes is detected. The effect of barbiturates on ALA synthetase can cause dangerous disease exacerbations in patients with porphyria. Primidone undergoes metabolism to phenylethylmalonamide and phenobarbital. The efficacy of primidone in treating essential tremor is not dependent on its phenobarbital metabolite.<xref ref-type="bibr" rid="article-18133.r20">[20]</xref></p>
        <p><bold>Elimination:</bold> About 25% of phenobarbital is excreted unchanged in the urine. The renal excretion can be increased by osmotic diuresis or alkalinization of the urine. The metabolic elimination of barbiturates is more rapid in young people than in older people and infants. Age-related changes have been demonstrated in pharmacokinetics due to slower clearance in older patients, resulting in higher serum concentrations with smaller drug doses.<xref ref-type="bibr" rid="article-18133.r34">[34]</xref>&#x000a0;In children, a shorter elimination half-time occurs due to greater clearance.<xref ref-type="bibr" rid="article-18133.r31">[31]</xref>&#x000a0;The half-life of phenobarbital decreases by approximately 4.6 hours/day on chronic administration.<xref ref-type="bibr" rid="article-18133.r35">[35]</xref></p>
      </sec>
      <sec id="article-18133.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Barbiturates are&#x000a0;administered in oral and parenteral forms (intramuscular (IM) and IV).&#x000a0;IM injections of solutions of sodium salts such as phenobarbital or amobarbital should be administered in large muscle masses to avoid potential necrosis at superficial sites.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Phenobarbital:</bold> According to the American Epilepsy Society guidelines, phenobarbital 15 mg/kg in a single dose is suggested for status epilepticus (parenteral benzodiazepines are the first line choice).<xref ref-type="bibr" rid="article-18133.r36">[36]</xref>&#x000a0;When administered as an antiepileptic drug&#x000a0;for pediatric patients, phenobarbital may be given as an IV loading dose, followed by IV or oral administration.<xref ref-type="bibr" rid="article-18133.r37">[37]</xref>&#x000a0;</p>
        <p>In neonates, the&#x000a0;loading dose of phenobarbital is 20 mg/kg IV, and the maintenance dose is 3 to 4 mg/kg by mouth. Nonresponders should&#x000a0;be administered additional doses of 5 to 10 mg/kg&#x000a0;till seizure control. The indication for use typically determines the route of administration for adults. Maintenance therapy for antiepileptic drugs in adults generally is the oral route; other first-line drugs have replaced phenobarbital.<xref ref-type="bibr" rid="article-18133.r38">[38]</xref></p>
        <p><bold>Methohexital:</bold> Methohexital and thiopental may be administered rectally in pediatrics, particularly if the child cannot cooperate with IV needle administration. This method is best suited in procedures of short duration, such as radiology or dentistry. The usual&#x000a0;dose for methohexital is 1 to 1.5 mg/kg for induction.&#x000a0;Barbiturates administered for the induction of anesthesia in adults are most commonly given as an IV bolus for a rapid and pleasant loss of consciousness.<xref ref-type="bibr" rid="article-18133.r39">[39]</xref><xref ref-type="bibr" rid="article-18133.r40">[40]</xref></p>
        <p><bold>Thiopental:</bold> When using the IV route of administration in pediatrics, wide variation in the required dose&#x000a0;is noted. Cote recommended a higher dose range for unpremeditated children.<xref ref-type="bibr" rid="article-18133.r41">[41]</xref>&#x000a0;Thiopental was removed from the United States market in 2011 primarily based on the diversion of the drug within the&#x000a0;United States as a lethal injection drug.<xref ref-type="bibr" rid="article-18133.r42">[42]</xref></p>
        <p><bold>Pentobarbital:</bold> Pentobarbital is administered&#x000a0;by IM and IV routes. Pentobarbital is administered by&#x000a0;IM route 150 mg to 200 mg as a single-dose&#x000a0;pre-anesthetic medication. For status epilepticus, pentobarbital is given as a 5 to 15 mg/kg IV loading dose followed by a&#x000a0;continuous infusion&#x000a0;of 0.5 to 5 mg/kg/h. Continuous infusion dosing of pentobarbital is titrated electroencephalogram (EEG), following the guidelines set by the Neurocritical Care Society.<xref ref-type="bibr" rid="article-18133.r18">[18]</xref></p>
        <p><bold>Butalbital:</bold> Butalbital is used with aspirin-acetaminophen-caffeine for migraine and tension headaches. AAN does not endorse its use for a long&#x000a0;duration due to the risk of dependence and medication overuse headaches.<xref ref-type="bibr" rid="article-18133.r17">[17]</xref></p>
        <p><bold>Primidone:</bold> The usual starting dose of primidone is 100 to 125 mg at bedtime for seizure control in treatment-naive patients. The regular maintenance beyond&#x000a0;10 days is 250 mg, 3 times a day. The total daily dose of primidone should not exceed 2000 mg. Primidone is also used to treat essential tremors; the suggested starting dose is 25 mg daily, increasing&#x000a0;by 25 or 50 mg per month as tolerated.<xref ref-type="bibr" rid="article-18133.r43">[43]</xref></p>
        <p><bold>Amobarbital:</bold> The sedative&#x000a0;dose of amobarbital is&#x000a0;30 to 50 mg, given 2 or 3 times daily. The hypnotic&#x000a0;dose is 65 to 200 mg at bedtime.&#x000a0;Amobarbital&#x000a0;is a DEA-scheduled II substance, and agents with better safety profiles should be used due to misuse potential.<xref ref-type="bibr" rid="article-18133.r44">[44]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Renal impairment:</bold> No dose adjustment&#x000a0;is provided for methohexital. The use of thiopental is relatively contraindicated in renal disease. Dose reduction is recommended in phenobarbital. Nephrotoxicity is reported with an overdose of phenobarbital.<xref ref-type="bibr" rid="article-18133.r45">[45]</xref></p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No dose adjustment&#x000a0;is provided for methohexital. As phenobarbital undergoes extensive hepatic metabolism, dose reduction is advised.<xref ref-type="bibr" rid="article-18133.r46">[46]</xref></p>
        <p><bold>Pregnancy considerations:</bold> The placental transfer occurs within 1 minute of administration.<xref ref-type="bibr" rid="article-18133.r24">[24]</xref>&#x000a0;Neonatal depression may occur if&#x000a0;thiopental is used&#x000a0;as an induction agent for cesarean section. Methohexital can also cross the placental barrier. For general anesthesia, drugs&#x000a0;other than methohexital are recommended by ACOG (American College of Obstetricians and Gynecologists).<xref ref-type="bibr" rid="article-18133.r47">[47]</xref>&#x000a0;The use of phenobarbitone is&#x000a0;associated with major malformations. Antiepileptic agents, lamotrigine and levetiracetam, are preferred during pregnancy.<xref ref-type="bibr" rid="article-18133.r48">[48]</xref><xref ref-type="bibr" rid="article-18133.r49">[49]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Clinical data on the effects of phenobarbital&#x000a0;indicate that inter and intrapatient variability of excretion&#x000a0;in breast milk is apparent.&#x000a0;Phenobarbital can cause drowsiness in infants, especially when used with other sedating drugs. In a series of breastfeeding infants, for each mg/kg of phenobarbital taken by mothers, the infant's serum concentration increased by 2 to 5 mg/L. Several case reports exist of infant sedation occurring in mothers treated with phenobarbital.&#x000a0;Consequently, the infant&#x000a0;requires monitoring drowsiness and weight gain, especially in younger, exclusively breastfed infants. If excessive&#x000a0;sedation ensues, discontinuation of breastfeeding is suggested.<xref ref-type="bibr" rid="article-18133.r50">[50]</xref>&#x000a0;</p>
        <p>Concerning the short-acting IV barbiturates, methohexital was found in breastmilk at the highest concentrations 1 to 2 hours after an IV dose and undetectable 24 to 48 hours after an IV dose.<xref ref-type="bibr" rid="article-18133.r51">[51]</xref>&#x000a0;For thiopental, when used for induction of anesthesia for cesarean section, the highest concentration of thiopental in breast milk was in the first nursing after anesthesia, about 0.9 mg/L.&#x000a0;Breastfeeding can be resumed as soon as the mother has recovered sufficiently from general anesthesia. However, if a combination of&#x000a0;drugs is used during the procedure, follow the&#x000a0;standard operating procedure considering the elimination half-life of each agent.<xref ref-type="bibr" rid="article-18133.r52">[52]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>In the pediatric population, the therapeutic approach for refractory and super-refractory status epilepticus (RSE/SRSE) involves using barbiturates such as&#x000a0;phenobarbitone&#x000a0;and thiopental for coma induction. These drugs act on GABA receptors, inhibiting <italic toggle="yes">N</italic>-methyl-D-aspartate (NMDA) receptors. While effective in controlling seizures, unique considerations exist in the pediatric population. Barbiturates, including thiopental, may have a prolonged recovery time and have adverse&#x000a0;effects such as hypotension and respiratory depression, which may have specific implications in pediatric patients.</p>
        <p>Careful monitoring and individualized dosing are essential, and the decision-making process should consider the potential risks and benefits, considering the patient's age, weight, and overall health status. The treatment approach in pediatric RSE/SRSE involves a tailored, trial-and-error strategy due to the limited evidence and variability in individual responses.<xref ref-type="bibr" rid="article-18133.r53">[53]</xref>&#x000a0;Guidelines for severe pediatric TBI emphasize&#x000a0;ICP control. In cases of refractory intracranial hypertension persisting&#x000a0;after maximal medical and surgical interventions, the use of high-dose barbiturate therapy is recommended for hemodynamically stable patients. However, when implementing high-dose barbiturate therapy to address refractory intracranial hypertension, continuous monitoring of arterial blood pressure and providing cardiovascular support to uphold adequate cerebral perfusion pressure are imperative. This is crucial due to the common occurrence of cardiorespiratory instability in patients undergoing barbiturate coma.<xref ref-type="bibr" rid="article-18133.r54">[54]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;As per the American Geriatrics Society (AGS) 2023 Beers Criteria, the use of barbiturates, including butalbital, phenobarbital, and primidone, is discouraged due to a high rate of physical dependence, development of tolerance to sleep benefits, and an increased risk of overdose at low dosages. The use of these medications&#x000a0;is avoided in older adults.<xref ref-type="bibr" rid="article-18133.r55">[55]</xref></p>
      </sec>
      <sec id="article-18133.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>For women taking phenobarbital as monotherapy, the drug correlates with congenital defects in exposed infants.<xref ref-type="bibr" rid="article-18133.r5">[5]</xref></p>
        <p>When given in IV anesthetics, barbiturates produce a reduction in blood pressure and an increase in heart rate. Respiratory depression and apnea may occur.<xref ref-type="bibr" rid="article-18133.r24">[24]</xref></p>
        <p>Thiopental and thiamylal release histamine, while methohexital and pentobarbital have minimal histamine release.<xref ref-type="bibr" rid="article-18133.r56">[56]</xref></p>
        <p>Extravasation of thiopental (a vesicant) may cause severe tissue necrosis. If extravasation occurs, treatment measures include hyaluronidase and phentolamine.<xref ref-type="bibr" rid="article-18133.r57">[57]</xref>&#x000a0;Case reports of successful treatment also include the topical application of a eutectic mixture of local anesthetics and the local injection of lidocaine.<xref ref-type="bibr" rid="article-18133.r58">[58]</xref></p>
        <p>Barbiturates such as butalbital can lead to withdrawal symptoms, including seizures. The recommended risk mitigation strategy is to taper off barbituates under supervision.<xref ref-type="bibr" rid="article-18133.r15">[15]</xref></p>
        <p>
<bold>Hepatotoxicity</bold>
</p>
        <p>Barbiturates can cause allergic reactions and skin rashes associated with mild liver injury. Phenobarbital is predominantly linked with drug-induced liver injury. Phenobarbital-induced severe adverse drug reactions are DRESS (drug reaction with eosinophilia and systemic symptoms), Stevens-Johnson syndrome, and toxic epidermal necrolysis.<xref ref-type="bibr" rid="article-18133.r59">[59]</xref></p>
        <p>
<bold>Drug-Drug Interactions&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Phenobarbital is an inducer of the cytochrome enzyme system, specifically the CYP1A2, 2B6, 2C9, and 3A4/5 isozymes that will reduce the efficacy of warfarin, steroids, psychoactive drugs, and immunosuppressants.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Phenobarbital will also lower the plasma concentrations of other antiepileptic drugs, such as lamotrigine, oxcarbazepine, phenytoin, tiagabine, and valproate.<xref ref-type="bibr" rid="article-18133.r60">[60]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Contraceptive failure can occur when&#x000a0;systemic hormonal contraception drugs are&#x000a0;administered with enzyme inducers like phenobarbital.<xref ref-type="bibr" rid="article-18133.r61">[61]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Phenobarbital is a strong CYP3A4 inducer; avoid combination with hepatitis C drugs paritaprevir-ritonavir, ombitasvir, and dasabuvir.<xref ref-type="bibr" rid="article-18133.r62">[62]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As primidone is a CYP3A4 inducer, combining it with apremilast is strictly contraindicated.<xref ref-type="bibr" rid="article-18133.r63">[63]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When barbiturates are combined&#x000a0;with other CNS depressants, such as benzodiazepines and opioids, they can cause oversedation and severe&#x000a0;respiratory&#x000a0;depression.<xref ref-type="bibr" rid="article-18133.r64">[64]</xref><xref ref-type="bibr" rid="article-18133.r65">[65]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18133.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warnings</bold>
</p>
        <p>
<bold>Methohexital</bold>
</p>
        <p>Methohexital should be administered exclusively in hospitals or ambulatory care settings equipped to continuously monitor respiratory functions, such as pulse oximetry and cardiac activity. The immediate availability of resuscitative drugs is imperative, as well as age-appropriate equipment for ventilation and intubation. Healthcare professionals proficient in airway management should be consulted.</p>
        <p>
<bold>Phenobarbital</bold>
</p>
        <p>The risks associated with the concomitant use of phenobarbital and opioids include profound sedation, respiratory depression, coma, and death.&#x000a0;Concomitant prescribing should be reserved for cases where alternative treatments are insufficient. If combined, dosage and duration should be minimized, and patients should be monitored for sedation and respiratory depression.<xref ref-type="bibr" rid="article-18133.r66">[66]</xref> Prolonged use of phenobarbital may lead to physical dependence, with withdrawal risks increasing with duration and dosage. Although indicated for short-term use, exceeding recommended durations may necessitate a gradual taper to mitigate life-threatening withdrawal reactions. In addition, phenobarbital is not approved for use in adolescents or adults, exposing them to potential risks of abuse, misuse, and addiction, with concomitant use of other substances&#x000a0;increasing the likelihood of serious adverse outcomes.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Absolute contraindications for any barbiturate include status asthmaticus and acute and intermittent variegate porphyria.<xref ref-type="bibr" rid="article-18133.r24">[24]</xref>&#x000a0;Hypersensitivity to&#x000a0;barbiturates or excipients is a contraindication to their use. Hypersensitivity reactions, including anaphylaxis, have been reported. Barbiturates can trigger&#x000a0;hypersensitivity reactions by direct histamine release or immunoglobulin E&#x02013;mediated mechanisms.<xref ref-type="bibr" rid="article-18133.r67">[67]</xref></p>
      </sec>
      <sec id="article-18133.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Monitoring for Misuse</bold>
</p>
        <p>In response to the abuse potential of barbiturates, restricted access was initiated with the enactment of the Federal Comprehensive Drug Abuse and Control Act of 1970. Barbiturates are categorized as Schedule II to IV substances, reflecting their varying levels of abuse potential.<xref ref-type="bibr" rid="article-18133.r68">[68]</xref></p>
        <p>
<bold>Evaluation and Monitoring for Anesthesia</bold>
</p>
        <p>Pre-anesthetic evaluation is required when barbiturates are used for general anesthesia. The Revised Cardiac Risk Index for Pre-Operative Risk (RCRI) is a tool used to estimate the risk of cardiac complications following noncardiac surgery.<xref ref-type="bibr" rid="article-18133.r69">[69]</xref> Guidelines from the American Society of Anesthesiologists (ASA) advocate for monitoring oxygenation, ventilation, circulation, and temperature during anesthesia, as outlined in the Standards for Basic Anesthetic Monitoring. Additionally, the ASA Task Force on postanesthetic care recommends monitoring mental status, patient temperature, pain, nausea and vomiting, and volume status.<xref ref-type="bibr" rid="article-18133.r70">[70]</xref></p>
        <p>
<bold>Development of Tolerance and Dependence</bold>
</p>
        <p>Tolerance is a gradual loss of effectiveness such that the dose has to be increased to maintain the same effect.<xref ref-type="bibr" rid="article-18133.r27">[27]</xref>&#x000a0;This effect is&#x000a0;partly explained&#x000a0;by enzyme induction in the liver. Animal models have demonstrated tolerance. Withdrawal symptoms may manifest, with nervousness, tremors, agitation, and hypotension potentially developing 2 to 8 days after the abrupt discontinuation of barbiturates. In more severe cases, the patient may experience delirium or grand mal seizures.<xref ref-type="bibr" rid="article-18133.r27">[27]</xref>&#x000a0;</p>
        <p>Phenobarbital has a narrow therapeutic range of 10 to 30 mg/L, and its fatal dose is 80 mg/L.<xref ref-type="bibr" rid="article-18133.r71">[71]</xref> A Cochrane review found no clear evidence of a benefit to routine serum monitoring drug concentrations for antiepileptic drugs. Dose titration to control seizures was found to be effective.<xref ref-type="bibr" rid="article-18133.r72">[72]</xref>&#x000a0;A case report underscores the potential for tolerance, dependence, and misuse associated with butalbital-containing combination analgesics, urging careful consideration in patients presenting with new-onset psychosis. The patient's prolonged daily use of butalbital-containing medication and subsequent admission to a drug rehabilitation facility emphasizes the critical need to recognize and address the potential for misuse early in the clinical setting.<xref ref-type="bibr" rid="article-18133.r15">[15]</xref></p>
      </sec>
      <sec id="article-18133.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Acute barbiturate toxicity can arise from intentional or unintentional overdose. Barbiturates, with a history of abuse, were associated with 8469 cases of poisoning, according to data from the New York City Health Department, spanning the period from 1957 through 1963.<xref ref-type="bibr" rid="article-18133.r73">[73]</xref>&#x000a0;Overdosage of phenobarbital symptoms includes CNS depression, respiratory failure, and hemodynamic instability.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No specific antidote exists for barbiturates, and overdose treatment includes supportive care and urinary alkalinization.<xref ref-type="bibr" rid="article-18133.r71">[71]</xref>&#x000a0;A systematic review demonstrates&#x000a0;the efficacy of&#x000a0;multiple-dose activated charcoal&#x000a0;for phenobarbital and primidone overdose. Hemodialysis and haemoperfusion may be considered in patients&#x000a0;with life-threatening barbiturate toxicity.<xref ref-type="bibr" rid="article-18133.r74">[74]</xref>&#x000a0;Extracorporeal clearance with dialysis can augment drug elimination in cases of severe butalbital overdose.<xref ref-type="bibr" rid="article-18133.r75">[75]</xref>&#x000a0;During recovery, patients with chronic barbiturate misuse can present with seizures and autonomic instability.<xref ref-type="bibr" rid="article-18133.r15">[15]</xref></p>
      </sec>
      <sec id="article-18133.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Barbiturates have historically been a widely prescribed class of drugs&#x000a0;in outpatient and inpatient settings. Barbiturates are classified as controlled substances, necessitating adherence to all DEA prescription requirements. The prescription drug monitoring program serves to identify potential misuse and abuse.<xref ref-type="bibr" rid="article-18133.r76">[76]</xref>&#x000a0;Benzodiazepines have primarily replaced them when used for anti-anxiety or insomnia.</p>
        <p>The utilization of barbiturates for IV anesthesia has significantly diminished for the following 2 primary reasons:</p>
        <list list-type="bullet">
          <list-item>
            <p>After 2011, leading manufacturers ceased the production of thiopental or methohexital.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Propofol has emerged as the favored routine IV anesthetic induction agent owing to its ready availability, rapid onset, and quick offset.</p>
          </list-item>
        </list>
        <p>Phenobarbital continues to be used as a second-line antiepileptic drug in the United States and has frequent use in low-resource countries as a first-line drug due to its low cost.&#x000a0;The systematic review and meta-analysis concluded that phenobarbital is an effective tool in the management of alcohol withdrawal syndrome in an ICU setting.<xref ref-type="bibr" rid="article-18133.r77">[77]</xref> All healthcare professionals, including physicians and nurse practitioners who prescribe these agents, must be fully aware of the&#x000a0;adverse drug reactions, misuse, drug-drug interactions, and the potential to develop physical dependence.</p>
        <p>When barbiturates&#x000a0;are used in&#x000a0;anesthesia, supervision by anesthetics and certified registered nurse anesthetists is necessary. Movement disorder specialists should oversee the use of primidone for essential tremors. Given the potential for severe adverse events, including death, a pharmacist should verify the dosing and perform a thorough medication reconciliation to ensure no drug interactions, particularly additive CNS-depressing effects.</p>
        <p>The healthcare team must be proficient in resuscitating a patient in the event of an overdose, often necessitating MICU-level care and consultation with a critical care clinician. In cases of severe overdose, consultation with a toxicologist is advisable. A psychiatrist should be consulted once the patient has recovered in case of an overdose. The prescription of barbiturates and subsequent monitoring necessitates an interprofessional team approach, fostering collaboration across various disciplines to achieve optimal patient outcomes in barbiturate therapy.</p>
      </sec>
      <sec id="article-18133.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18133&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18133">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18133/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18133">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-18133.s11">
        <fig id="article-18133.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Barbituric acid Contributed by PubChem Via https://pubchem.ncbi.nlm.nih.gov/compound/barbituric_acid</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="barbituric__acid__from__pubchem" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-18133.s12">
        <title>References</title>
        <ref id="article-18133.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sneyd</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Thiopental to desflurane - an anaesthetic journey. Where are we going next?</article-title>
            <source>Br J Anaesth</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>119</volume>
            <issue>suppl_1</issue>
            <fpage>i44</fpage>
            <page-range>i44-i52</page-range>
            <pub-id pub-id-type="pmid">29161390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Thiopentone and its challengers.</article-title>
            <source>Paediatr Anaesth</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>10</issue>
            <fpage>957</fpage>
            <page-range>957-8</page-range>
            <pub-id pub-id-type="pmid">23216953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prabhakar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kalaivani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Propofol versus thiopental sodium for the treatment of refractory status epilepticus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Feb</month>
            <day>03</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD009202</fpage>
            <pub-id pub-id-type="pmid">28155226</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruble</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The "death" of lethal injection as we know it? The role of chemical execution in the American criminal justice system.</article-title>
            <source>J Pain Palliat Care Pharmacother</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>276</fpage>
            <page-range>276-81</page-range>
            <pub-id pub-id-type="pmid">25121632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodie</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Current position of phenobarbital in epilepsy and its future.</article-title>
            <source>Epilepsia</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>53 Suppl 8</volume>
            <fpage>40</fpage>
            <page-range>40-6</page-range>
            <pub-id pub-id-type="pmid">23205961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadiyala</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Kadiyala</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Anaesthesia for electroconvulsive therapy: An overview with an update on its role in potentiating electroconvulsive therapy.</article-title>
            <source>Indian J Anaesth</source>
            <year>2017</year>
            <month>May</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>373</fpage>
            <page-range>373-380</page-range>
            <pub-id pub-id-type="pmid">28584345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haddad</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Arabi</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Critical care management of severe traumatic brain injury in adults.</article-title>
            <source>Scand J Trauma Resusc Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <day>03</day>
            <volume>20</volume>
            <fpage>12</fpage>
            <pub-id pub-id-type="pmid">22304785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majdan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mauritz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wilbacher</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brazinova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rusnak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leitgeb</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Barbiturates use and its effects in patients with severe traumatic brain injury in five European countries.</article-title>
            <source>J Neurotrauma</source>
            <year>2013</year>
            <month>Jan</month>
            <day>01</day>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-9</page-range>
            <pub-id pub-id-type="pmid">22950895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aneja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.</article-title>
            <source>Seizure</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>102</volume>
            <fpage>74</fpage>
            <page-range>74-82</page-range>
            <pub-id pub-id-type="pmid">36209676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Best evidence topic report. Procedural sedation for cardioversion.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>932</fpage>
            <page-range>932-4</page-range>
            <pub-id pub-id-type="pmid">17130605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Kelleman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Stockwell</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mallory</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of methohexital as an alternative to propofol in a high volume outpatient pediatric sedation service.</article-title>
            <source>Am J Emerg Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1101</fpage>
            <page-range>1101-1105</page-range>
            <pub-id pub-id-type="pmid">28330689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Biros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krieg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heegaard</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Randomized clinical trial of propofol versus methohexital for procedural sedation during fracture and dislocation reduction in the emergency department.</article-title>
            <source>Acad Emerg Med</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>9</issue>
            <fpage>931</fpage>
            <page-range>931-7</page-range>
            <pub-id pub-id-type="pmid">12957974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naulaers</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deloof</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vanhole</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Devlieger</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Use of methohexital for elective intubation in neonates.</article-title>
            <source>Arch Dis Child Fetal Neonatal Ed</source>
            <year>1997</year>
            <month>Jul</month>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>F61</fpage>
            <page-range>F61-4</page-range>
            <pub-id pub-id-type="pmid">9279186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bendtsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitsikostas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sandrini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schoenen</surname>
                <given-names>J</given-names>
              </name>
              <collab>EFNS</collab>
            </person-group>
            <article-title>EFNS guideline on the treatment of tension-type headache - report of an EFNS task force.</article-title>
            <source>Eur J Neurol</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>1318</fpage>
            <page-range>1318-25</page-range>
            <pub-id pub-id-type="pmid">20482606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodulfo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Augsten</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wainwright</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abramovici</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Case of Severe Fioricet Withdrawal Presenting During Admission to an Inpatient Psychiatric Unit.</article-title>
            <source>Case Rep Psychiatry</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>6371953</fpage>
            <pub-id pub-id-type="pmid">34790421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderPluym</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Halker Singh</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Urtecho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nayfeh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Torres Roldan</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abd-Rabu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daraz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jun</month>
            <day>15</day>
            <volume>325</volume>
            <issue>23</issue>
            <fpage>2357</fpage>
            <page-range>2357-2369</page-range>
            <pub-id pub-id-type="pmid">34128998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marmura</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.</article-title>
            <source>Headache</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-20</page-range>
            <pub-id pub-id-type="pmid">25600718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brophy</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shutter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Vespa</surname>
                <given-names>PM</given-names>
              </name>
              <collab>Neurocritical Care Society Status Epilepticus Guideline Writing Committee</collab>
            </person-group>
            <article-title>Guidelines for the evaluation and management of status epilepticus.</article-title>
            <source>Neurocrit Care</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">22528274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ghanchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Podkovik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miulli</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sweiss</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pentobarbital Coma With Therapeutic Hypothermia for Treatment of Refractory Intracranial Hypertension in Traumatic Brain Injury Patients: A Single Institution Experience.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Sep</month>
            <day>22</day>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>e10591</fpage>
            <pub-id pub-id-type="pmid">33110727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanker</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Essential tremor: diagnosis and management.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Aug</month>
            <day>05</day>
            <volume>366</volume>
            <fpage>l4485</fpage>
            <pub-id pub-id-type="pmid">31383632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sateia</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Neubauer</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Heald</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>J Clin Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <day>15</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>307</fpage>
            <page-range>307-349</page-range>
            <pub-id pub-id-type="pmid">27998379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chau</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>New insights into the molecular mechanisms of general anaesthetics.</article-title>
            <source>Br J Pharmacol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>161</volume>
            <issue>2</issue>
            <fpage>288</fpage>
            <page-range>288-307</page-range>
            <pub-id pub-id-type="pmid">20735416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;scher</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rogawski</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>How theories evolved concerning the mechanism of action of barbiturates.</article-title>
            <source>Epilepsia</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>53 Suppl 8</volume>
            <fpage>12</fpage>
            <page-range>12-25</page-range>
            <pub-id pub-id-type="pmid">23205959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martone</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Nagelhout</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Methohexital: a practical review for outpatient dental anesthesia.</article-title>
            <source>Anesth Prog</source>
            <year>1991</year>
            <season>Nov-Dec</season>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>195</fpage>
            <page-range>195-9</page-range>
            <pub-id pub-id-type="pmid">1842156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cozanitis</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>One hundred years of barbiturates and their saint.</article-title>
            <source>J R Soc Med</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>12</issue>
            <fpage>594</fpage>
            <page-range>594-8</page-range>
            <pub-id pub-id-type="pmid">15574863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of barbiturates.</article-title>
            <source>Annu Rev Pharmacol Toxicol</source>
            <year>1981</year>
            <volume>21</volume>
            <fpage>83</fpage>
            <page-range>83-111</page-range>
            <pub-id pub-id-type="pmid">6263177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Devenyi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Barbiturate abuse and addiction and their relationship to alcohol and alcoholism.</article-title>
            <source>Can Med Assoc J</source>
            <year>1971</year>
            <month>Feb</month>
            <day>06</day>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-8</page-range>
            <pub-id pub-id-type="pmid">4924250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus.</article-title>
            <source>BMC Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>06</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <pub-id pub-id-type="pmid">30954065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jalling</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Plasma concentrations of phenobarbital in the treatment of seizures in newborns.</article-title>
            <source>Acta Paediatr Scand</source>
            <year>1975</year>
            <month>May</month>
            <volume>64</volume>
            <issue>3</issue>
            <fpage>514</fpage>
            <page-range>514-24</page-range>
            <pub-id pub-id-type="pmid">1155069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanski</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Mihm</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kalman</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of high-dose thiopental used in cerebral resuscitation.</article-title>
            <source>Anesthesiology</source>
            <year>1980</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-71</page-range>
            <pub-id pub-id-type="pmid">7416528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorbo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Loomis</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics of thiopental in pediatric surgical patients.</article-title>
            <source>Anesthesiology</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>6</issue>
            <fpage>666</fpage>
            <page-range>666-70</page-range>
            <pub-id pub-id-type="pmid">6507924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanski</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Maitre</surname>
                <given-names>PO</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.</article-title>
            <source>Anesthesiology</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>412</fpage>
            <page-range>412-22</page-range>
            <pub-id pub-id-type="pmid">2310020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stanski</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>The role of metabolism and protein binding in thiopental anesthesia.</article-title>
            <source>Anesthesiology</source>
            <year>1983</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-52</page-range>
            <pub-id pub-id-type="pmid">6824168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Homer</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Stanski</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>The effect of increasing age on thiopental disposition and anesthetic requirement.</article-title>
            <source>Anesthesiology</source>
            <year>1985</year>
            <month>Jun</month>
            <volume>62</volume>
            <issue>6</issue>
            <fpage>714</fpage>
            <page-range>714-24</page-range>
            <pub-id pub-id-type="pmid">4003792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacifici</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics.</article-title>
            <source>Curr Pediatr Rev</source>
            <year>2016</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">26496779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shinnar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alldredge</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bare</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dodson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Garrity</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jagoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pellock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sloan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Treiman</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.</article-title>
            <source>Epilepsy Curr</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-61</page-range>
            <pub-id pub-id-type="pmid">26900382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moffett</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Weingarten</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Galati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Placencia</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Rodman</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Riviello</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kayyal</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Phenobarbital population pharmacokinetics across the pediatric age spectrum.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>1327</fpage>
            <page-range>1327-1333</page-range>
            <pub-id pub-id-type="pmid">29897629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nevitt</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sudell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weston</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tudur Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marson</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jun</month>
            <day>29</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD011412</fpage>
            <pub-id pub-id-type="pmid">28661008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Griswold</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Administration of methohexital for pediatric outpatient dentistry.</article-title>
            <source>Anesth Prog</source>
            <year>1990</year>
            <season>Sep-Oct</season>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>248</fpage>
            <page-range>248-51</page-range>
            <pub-id pub-id-type="pmid">2096749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Binns</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Rectal pentothal sedation for selected patients.</article-title>
            <source>Anesth Prog</source>
            <year>1975</year>
            <season>Sep-Oct</season>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>151</fpage>
            <page-range>151-4</page-range>
            <pub-id pub-id-type="pmid">1060389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cot&#x000e9;</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Goudsouzian</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Dedrick</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rosow</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>The dose response of intravenous thiopental for the induction of general anesthesia in unpremedicated children.</article-title>
            <source>Anesthesiology</source>
            <year>1981</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>703</fpage>
            <page-range>703-5</page-range>
            <pub-id pub-id-type="pmid">7305061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <collab>American Society of Anesthesiologists Task Force on Sedation and Analgesia by Non-Anesthesiologists</collab>
            <article-title>Practice guidelines for sedation and analgesia by non-anesthesiologists.</article-title>
            <source>Anesthesiology</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>1004</fpage>
            <page-range>1004-17</page-range>
            <pub-id pub-id-type="pmid">11964611</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Primidone Intolerance in Essential tremor: Is it More than Just Age?</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>57</fpage>
            <pub-id pub-id-type="pmid">35070493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caulkins</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Goyeneche</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lenart</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rath</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Outcomes associated with scheduling or up-scheduling controlled substances.</article-title>
            <source>Int J Drug Policy</source>
            <year>2021</year>
            <month>May</month>
            <volume>91</volume>
            <fpage>103110</fpage>
            <pub-id pub-id-type="pmid">33476862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>Managing the patient with epilepsy and renal impairment.</article-title>
            <source>Seizure</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>76</volume>
            <fpage>143</fpage>
            <page-range>143-152</page-range>
            <pub-id pub-id-type="pmid">32087549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patsalos</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update.</article-title>
            <source>Ther Drug Monit</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>526</fpage>
            <page-range>526-548</page-range>
            <pub-id pub-id-type="pmid">29957667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <collab>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins&#x02014;Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 209: Obstetric Analgesia and Anesthesia.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>e208</fpage>
            <page-range>e208-e225</page-range>
            <pub-id pub-id-type="pmid">30801474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedzelman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meador</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Antiepileptic drugs in women with epilepsy during pregnancy.</article-title>
            <source>Ther Adv Drug Saf</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-87</page-range>
            <pub-id pub-id-type="pmid">25083227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Pennell</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Management of epilepsy during pregnancy: an update.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-29</page-range>
            <pub-id pub-id-type="pmid">27006699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <chapter-title>Phenobarbital</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r51">
          <label>51</label>
          <element-citation publication-type="book">
            <chapter-title>Methohexital</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>12</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">30000358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r52">
          <label>52</label>
          <element-citation publication-type="book">
            <chapter-title>Thiopental</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vasquez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farias-Moeller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tatum</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pediatric refractory and super-refractory status epilepticus.</article-title>
            <source>Seizure</source>
            <year>2019</year>
            <month>May</month>
            <volume>68</volume>
            <fpage>62</fpage>
            <page-range>62-71</page-range>
            <pub-id pub-id-type="pmid">29941225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kochanek</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tasker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Carney</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Totten</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Adelson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Selden</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Davis-O'Reilly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bratton</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kissoon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reuter-Rice</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Vavilala</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Wainwright</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3S Suppl 1</issue>
            <fpage>S1</fpage>
            <page-range>S1-S82</page-range>
            <pub-id pub-id-type="pmid">30829890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirshman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Edelstein</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Ebertz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Hanifin</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Thiobarbiturate-induced histamine release in human skin mast cells.</article-title>
            <source>Anesthesiology</source>
            <year>1985</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>353</fpage>
            <page-range>353-6</page-range>
            <pub-id pub-id-type="pmid">2412468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Extravasation of Noncytotoxic Drugs: A Review of the Literature.</article-title>
            <source>Ann Pharmacother</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>870</fpage>
            <page-range>870-886</page-range>
            <pub-id pub-id-type="pmid">24714850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Hseu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>EMLA cream and lidocaine local injection in the treatment of extravenous thiopental injection--a case report.</article-title>
            <source>Acta Anaesthesiol Sin</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-6</page-range>
            <pub-id pub-id-type="pmid">9293651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r59">
          <label>59</label>
          <element-citation publication-type="book">
            <chapter-title>Barbiturates</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>10</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">31643584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brodie</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mintzer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pack</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gidal</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Vecht</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Enzyme induction with antiepileptic drugs: cause for concern?</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-27</page-range>
            <pub-id pub-id-type="pmid">23016553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mauskopf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Talbird</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antiseizure medications and oral contraceptives: Impact of enzyme inducers on pregnancy outcomes and costs.</article-title>
            <source>Epilepsy Behav</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>125</volume>
            <fpage>108368</fpage>
            <pub-id pub-id-type="pmid">34775242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Badri</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Polepally</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Zha</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Coakley</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Podsadecki</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Awni</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Dutta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.</article-title>
            <source>J Hepatol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-9</page-range>
            <pub-id pub-id-type="pmid">25646891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmisano</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>78</volume>
            <issue>5</issue>
            <fpage>1050</fpage>
            <page-range>1050-7</page-range>
            <pub-id pub-id-type="pmid">24962564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savelloni</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gunter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Edmonds</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Furnish</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Atayee</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Risk of respiratory depression with opioids and concomitant gabapentinoids.</article-title>
            <source>J Pain Res</source>
            <year>2017</year>
            <volume>10</volume>
            <fpage>2635</fpage>
            <page-range>2635-2641</page-range>
            <pub-id pub-id-type="pmid">29180889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;jehagen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000e5;kansson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>174</volume>
            <fpage>58</fpage>
            <page-range>58-64</page-range>
            <pub-id pub-id-type="pmid">28315808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Swedler</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rockett</surname>
                <given-names>IRH</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Leonardo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incidence and Lethality of Suicidal Overdoses by Drug Class.</article-title>
            <source>JAMA Netw Open</source>
            <year>2020</year>
            <month>Mar</month>
            <day>02</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>e200607</fpage>
            <pub-id pub-id-type="pmid">32202643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monta&#x000f1;ez</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mayorga</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bogas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barrionuevo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fernandez-Santamaria</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martin-Serrano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laguna</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Do&#x000f1;a</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis.</article-title>
            <source>Front Immunol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>614</fpage>
            <pub-id pub-id-type="pmid">28611774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabay</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The federal controlled substances act: schedules and pharmacy registration.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>473</fpage>
            <page-range>473-4</page-range>
            <pub-id pub-id-type="pmid">24421507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roshanov</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devereaux</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>MacNeil</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Hildebrand</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Acedillo</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Mrkobrada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Thabane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>External validation of the Revised Cardiac Risk Index and update of its renal variable to predict 30-day risk of major cardiac complications after non-cardiac surgery: rationale and plan for analyses of the VISION study.</article-title>
            <source>BMJ Open</source>
            <year>2017</year>
            <month>Jan</month>
            <day>09</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>e013510</fpage>
            <pub-id pub-id-type="pmid">28069624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apfelbaum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Connis</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Fillmore</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Nickinovich</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Schreiner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Apfelbaum</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Connis</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Fillmore</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Joas</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Nickinovich</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Schreiner</surname>
                <given-names>MS</given-names>
              </name>
              <collab>American Society of Anesthesiologists Task Force on Postanesthetic Care</collab>
            </person-group>
            <article-title>Practice guidelines for postanesthetic care: an updated report by the American Society of Anesthesiologists Task Force on Postanesthetic Care.</article-title>
            <source>Anesthesiology</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>118</volume>
            <issue>2</issue>
            <fpage>291</fpage>
            <page-range>291-307</page-range>
            <pub-id pub-id-type="pmid">23364567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoyland</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wildman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful use of haemodialysis to treat phenobarbital overdose.</article-title>
            <source>BMJ Case Rep</source>
            <year>2013</year>
            <month>Nov</month>
            <day>21</day>
            <volume>2013</volume>
            <pub-id pub-id-type="pmid">24265338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kimland</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic monitoring of antiepileptic drugs for epilepsy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Jan</month>
            <day>24</day>
            <volume>2007</volume>
            <issue>1</issue>
            <fpage>CD002216</fpage>
            <pub-id pub-id-type="pmid">17253477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>BUCOVE</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>MISUSE OF VALUABLE THERAPEUTIC AGENTS: BARBITURATES, TRANQUILIZERS, AND AMPHETAMINES.</article-title>
            <source>Bull N Y Acad Med</source>
            <year>1964</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>972</fpage>
            <page-range>972-9</page-range>
            <pub-id pub-id-type="pmid">14232143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Enhanced elimination in acute barbiturate poisoning - a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-12</page-range>
            <pub-id pub-id-type="pmid">21288146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poyant</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Albright</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pandompatam</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barreto</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>439</fpage>
            <page-range>439-441</page-range>
            <pub-id pub-id-type="pmid">29124988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weaver</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Prescription Sedative Misuse and Abuse.</article-title>
            <source>Yale J Biol Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>88</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-56</page-range>
            <pub-id pub-id-type="pmid">26339207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18133.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Haseeb Ul Rasool</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muhammad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yousaf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nassar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilyas</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hosna</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Parikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhangal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ariyaratnam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trandafirescu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Phenobarbital and Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>e33695</fpage>
            <pub-id pub-id-type="pmid">36788902</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
